Merck Out-Licenses Gene Therapy Assets To FKD Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Finland's FKD Therapies set up to exploit Merck & Co's gene therapy assets, and expects to start Phase II trials of a bladder cancer therapeutic in 2012.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011
Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
Former Big Pharma execs are finding homes in Chinese start-ups like BeiGene Ltd., where they are leveraging their industry knowledge and contacts to bring in deals focused on Asian populations.